Results 81 to 90 of about 11,390 (145)

Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United States. [PDF]

Breast
Mahtani R, Korytowsky B, Rose CG, Jakobsson M, Cappelleri J, Lewis K, Lambert A, Hammond C, Criscitiello C.   +8 more
europepmc   +1 more source

Selective oestrogen receptor modulators and Alzheimer´s disease: a real-world pharmacovigilance study. [PDF]

Eur J Clin Pharmacol
Yuste MT, Badillo E, Galecio JS, Marín P.   +3 more
europepmc   +1 more source

Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer. [PDF]

Breast Cancer Res
Lei L, Bhave M, Kalinsky K, Gandhi S.
europepmc   +1 more source

Estradiol levels in women with hormone receptor-positive advanced breast cancer on fulvestrant therapy. [PDF]

Oncologist
Dai S, Wen Y, Wu X, Wang X, Yuan Z, Xu F, Xie X, Xia W, Wang S, Shi Y, Liu P, Zheng Q, Tang J, An X, Huang J, Chen M, Zhong Y, Bi X, Yang Y, Xue C.   +19 more
europepmc   +1 more source

Sexual dimorphism in keratoconus: transcriptomic and hormonal mechanisms underlying stromal remodelling. [PDF]

Eye Vis (Lond)
Sun Y, Li Q, Wu X, Yu X, Wang R, Sun B, Wang K, Yu Y, Chen S, Jiang D, Chen W.   +10 more
europepmc   +1 more source

CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. [PDF]

Nat Commun
Luo L, Wang Y, Bui T, Jiang X, Chen MK, Rao X, Mohammadhosseinpour S, Li M, Kim S, Kim RY, Kamaliasl S, Ulizio CW, Tsavachidis S, Navarro-Yepes J, Kettner NM, Wingate H, Meric-Bernstam F, Hunt KK, Wang J, Faia K, Keyomarsi K.   +20 more
europepmc   +1 more source

Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study. [PDF]

Curr Oncol
Rayson D, Bertin J, Lemelin M, Tong M, Ng R, Ding P, Cheung WY, Sharma A, On PV, Feugère G, Lupichuk S.   +10 more
europepmc   +1 more source

Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer. [PDF]

Breast Cancer Res
Shen S, Teysir J, Safonov A, Bromberg M, Chen Y, Ahmed M, Razavi P, Jhaveri K.   +7 more
europepmc   +1 more source

Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR⁺/HER2^-advanced breast cancer. [PDF]

Breast
Zhu J, Ding Y, Li Z, Liu W.
europepmc   +1 more source

Targeting the ERα DBD-LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation. [PDF]

Mol Cancer Ther
Wang H, Luo Y, Artham S, Wang Q, Peng Y, Yun Z, Li X, Wu C, Liu Z, Weber-Bonk KL, Pai CP, Cao Y, Yue J, Park S, Keri RA, Geng L, McDonnell DP, Kao HY, Yang S.   +18 more
europepmc   +1 more source